trial
as of 2026-07-01Berberine as Adjuvant Treatment for Schizophrenia Patients
NCTId NCT02983188
at a glance
Phase 2, Phase 3 · Completed
Enrollment 113 (actual)
Sponsored by The University of Hong Kong
Primary completion 2020-12-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2, Phase 3
Status
Completed
Enrollment
113 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2018-04-25
Primary completion
2020-12-30
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
The University of Hong KongLead Sponsor
Queen Mary Hospital, Hong KongCollaborator
Kowloon Hospital, Hong KongCollaborator
Castle Peak HospitalCollaborator
Zhejiang Provincial Tongde HospitalCollaborator
Investigators
1
Zhang-Jin ZHANG, MMed, PhDPrincipal Investigator
Sites
1 total
Tuenmen, Hong Kong
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
113
Phase
PHASE2,PHASE3
Primary Completion Date
2020-12-30
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
indication
investigator